

## QIBA Lung Nodule Assessment in CT Screening Writing Group

22 August 2013 at 3 PM CDT

Draft Call Summary

### In attendance:

James L. Mulshine, MD (Co-Chair)  
Rick Avila, MS  
Andrew Buckler, MS  
Charles Fenimore, PhD  
Matthew Fuld, PhD

Gregory Goldmacher, MD, PhD  
Philip Judy, PhD  
Zachary Levine, PhD  
Anthony Reeves, PhD  
David Yankelevitz, MD

### RSNA:

Joe Koudelik  
Julie Lisiecki

### Presentation Highlights

Mr. Avila gave a presentation on the Roche ABIGAIL ([A](#)vastin [B](#)iomarkers [I](#)n LunG [A](#)nd 3D [I](#)nnovative Ana[L](#)ysis) study at ECR 2013

**Presentation topic:** Calibration of computed tomography (CT) – volumetric measurements for assessing tumor response to drug therapy in a randomized multicenter oncology study

**Goal of the ABIGAIL study:** to quantify tumor diameter and volumetric measurement variability due to CT acquisition properties for patients participating in a clinical NSCLC trial

- Calibrated object, e.g. a pocket phantom imaged with the patient, should show no change

Analysis was done by comparing volumetric measurements with RECIST

- Considerable variability associated with image acquisition protocols and older (i.e. 8-slice) scanners
- Point-of-interest made that many older scanners will simply not meet the current performance requirements of quantitative imaging
- This data will help the group to design requirements and performance parameters for the Profile

### Action items

Group to consider how data from the ABIGAIL study might be integrated into the Profile

Group asked to review markups to the document that is currently available on the [QIBA wiki](#)

**Next call** will be **Thursday, September 5<sup>th</sup> at 3 PM (CDT) – (?)**

### RSNA 2013 Annual Meeting - QIBA Technical Committees Working Meeting:

Wednesday, December 4<sup>th</sup> | 3:00pm – 5:00pm | Chicago, McCormick Place | Room: TBD

Please let us know whether you plan to attend by responding to the following poll:

<http://www.doodle.com/fwf76cegb78r75b>.

We appreciate your continued support and look forward to your participation - Thank You!